115 related articles for article (PubMed ID: 32887532)
21. Type II transmembrane serine proteases in cancer and viral infections.
Choi SY; Bertram S; Glowacka I; Park YW; Pöhlmann S
Trends Mol Med; 2009 Jul; 15(7):303-12. PubMed ID: 19581128
[TBL] [Abstract][Full Text] [Related]
22. Human airway trypsin-like protease, a serine protease involved in respiratory diseases.
Menou A; Duitman J; Flajolet P; Sallenave JM; Mailleux AA; Crestani B
Am J Physiol Lung Cell Mol Physiol; 2017 May; 312(5):L657-L668. PubMed ID: 28235951
[TBL] [Abstract][Full Text] [Related]
23. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium.
Böttcher E; Matrosovich T; Beyerle M; Klenk HD; Garten W; Matrosovich M
J Virol; 2006 Oct; 80(19):9896-8. PubMed ID: 16973594
[TBL] [Abstract][Full Text] [Related]
24. Repurposing and discovery of transmembrane serine protease 2 (TMPRSS2) inhibitors as prophylactic therapies for new coronavirus disease 2019 (COVID-19).
Yang H; Lin X; Yu Q; Awadasseid A; Zhang W
Pharmazie; 2023 Dec; 78(11):217-224. PubMed ID: 38178286
[TBL] [Abstract][Full Text] [Related]
25. TMPRSS2 Activates Hemagglutinin-Esterase Glycoprotein of Influenza C Virus.
Sato K; Hayashi H; Shimotai Y; Yamaya M; Hongo S; Kawakami K; Matsuzaki Y; Nishimura H
J Virol; 2021 Oct; 95(21):e0129621. PubMed ID: 34406864
[TBL] [Abstract][Full Text] [Related]
26. Influenza virus activating host proteases: Identification, localization and inhibitors as potential therapeutics.
Garten W; Braden C; Arendt A; Peitsch C; Baron J; Lu Y; Pawletko K; Hardes K; Steinmetzer T; Böttcher-Friebertshäuser E
Eur J Cell Biol; 2015; 94(7-9):375-83. PubMed ID: 26095298
[TBL] [Abstract][Full Text] [Related]
27. In vitro testing of host-targeting small molecule antiviral matriptase/TMPRSS2 inhibitors in 2D and 3D cell-based assays.
van Eijk N; Schmacke LC; Steinmetzer T; Pilgram O; Poór M; Pászti-Gere E
Biomed Pharmacother; 2023 Dec; 168():115761. PubMed ID: 37865989
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
29. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
30. TMPRSS4, a type II transmembrane serine protease, as a potential therapeutic target in cancer.
Kim S
Exp Mol Med; 2023 Apr; 55(4):716-724. PubMed ID: 37009799
[TBL] [Abstract][Full Text] [Related]
31. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation.
Meyer D; Sielaff F; Hammami M; Böttcher-Friebertshäuser E; Garten W; Steinmetzer T
Biochem J; 2013 Jun; 452(2):331-43. PubMed ID: 23527573
[TBL] [Abstract][Full Text] [Related]
32. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
33. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-κb pathways in non-pregnant and pregnant populations.
Celik O; Celik N; Aydin S; Baysal B; Aydin S; Saglam A; Gursu Y; Dalkilic S; Ulas M; Ozcil MD; Tayyar AT; Cengiz F; Ugur K; Akkoc RF; Ersahin AA
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):221-229. PubMed ID: 32538775
[TBL] [Abstract][Full Text] [Related]
34. Optimization of Ketobenzothiazole-Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication.
Colombo É; Désilets A; Hassanzadeh M; Lemieux G; Marois I; Cliche D; Delbrouck JA; Murza A; Jean F; Marsault E; Richter MV; Leduc R; Boudreault PL
ChemMedChem; 2024 Jan; 19(2):e202300458. PubMed ID: 37864572
[TBL] [Abstract][Full Text] [Related]
35. Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.
Damalanka VC; Wildman SA; Janetka JW
Medchemcomm; 2019 Sep; 10(9):1646-1655. PubMed ID: 31803403
[TBL] [Abstract][Full Text] [Related]
36. Structure-Based Design of High-Affinity and Selective Peptidomimetic Hepsin Inhibitors.
Knaff PM; Müller P; Kersten C; Wettstein L; Münch J; Landfester K; Mailänder V
Biomacromolecules; 2022 Jun; 23(6):2236-2242. PubMed ID: 35593713
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
38. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
[No Abstract] [Full Text] [Related]
40. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
